Fresenius Medical Care AG
NYSE•FMS
CEO: Ms. Helen Giza
Sector: Healthcare
Industry: Medical - Care Facilities
Listing Date: 1996-09-17
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. It also develops, manufactures, and distributes various health care products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products. In addition, the company develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. Fresenius Medical Care AG was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
Contact Information
Market Cap
$13.13B
P/E (TTM)
11.6
16.3
Dividend Yield
3.5%
52W High
$30.46
52W Low
$20.95
52W Range
Rank36Top 31.8%
4.5
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 4.5 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q4 2025 Data
Revenue
$5.90B+0.00%
4-Quarter Trend
EPS
$0.66+0.00%
4-Quarter Trend
FCF
$656.78M+0.00%
4-Quarter Trend
2025 Annual Earnings Highlights
Key Highlights
Revenue Growth Strong Total revenue reached €19.63 B, up 2% as reported; Constant Currency revenue grew 5% across segments.
Operating Income Jumps Operating income €1.83 B, up 31% reported, driven by segment growth and FME25+ net savings.
Shareholder Net Income Net income attributable to shareholders €978 M, up 88% in Constant Currency, showing strong profitability improvement.
HVHDF Standard Set Introduced HVHDF into clinical practice in U.S. clinics, planning broader commercial launch in 2026 for advanced therapy.
Risk Factors
Regulatory Uncertainty High Legislative reform threats, including ACA changes and Loper Bright ruling, create uncertainty for reimbursement models.
Cost Inflation Pressures Increased costs for labor, energy, and raw materials may adversely impact financial condition if not offset by pricing.
Cybersecurity Incident Risk IT systems were attacked in 2023; continuous monitoring needed to safeguard confidential patient and business data.
Reimbursement Rate Decline Government payor reimbursement rates are limited, potentially shifting commercially insured patients to lower-paying systems.
Outlook
FME Reignite Strategy Focus Strategy aims for above-market growth and industry-leading margins, building on portfolio reorganization and innovation.
FME25+ Savings Target Expanded FME25+ Program targets cumulative €1.2 BN sustainable savings by the end of 2027 across operations.
Capital Allocation Framework Framework includes 30% to 40% dividend payout ratio and €1 BN share buyback program completion expected soon.
HVHDF Rollout Planned Committed to replacing entire U.S. installed base with 5008X CAREsystem by end of 2030 to drive therapy adoption.
Peer Comparison
Revenue (TTM)
$22.15B
$21.31B
$17.36B
Gross Margin (Latest Quarter)
100.0%
90.9%
65.6%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| THC | $20.01B | 14.2 | 34.8% | 44.4% |
| RPRX | $19.56B | 25.6 | 11.9% | 45.6% |
| INCY | $18.42B | 14.2 | 29.1% | 1.0% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
4.7%
Moderate Growth
4Q Net Income CAGR
33.7%
Profitability Improved
Cash Flow Stability
100%
Strong Cash Flow
Deep Research
Next earnings:May 4, 2026
EPS:-
|Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data